FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office
Drug industry officials and analysts praised the FDA’s plans to streamline regulation of “biosimilars,” which are cheaper alternatives to biologic drugs. But patents that block such drugs from the U.S. market are getting harder to fight.